The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Research Report 2025
Synopsis
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market was valued at US$ 14620 million in 2023 and is anticipated to reach US$ 38900 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.
Report Scope
The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Segment by Type
Therapeutics
Diagnostics
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-alcoholic steatohepatitis (NASH), also known as non-alcoholic fatty liver disease (NAFLD), is a disease caused by excessive accumulation of fat in the liver.
The global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market was valued at US$ 14620 million in 2023 and is anticipated to reach US$ 38900 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics.
Report Scope
The Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
Segment by Type
Therapeutics
Diagnostics
Segment by Application
Hospital
Clinic
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Therapeutics
1.2.3 Diagnostics
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Perspective (2019-2030)
2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Growth Trends by Region
2.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Region (2019-2024)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Region (2025-2030)
2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Players (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023
3.5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Type (2019-2024)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2025-2030)
5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Historic Market Size by Application (2019-2024)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2019-2030)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2019-2030)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2019-2030)
8.2 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2019-2030)
9.2 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024)
9.4 Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (2019-2030)
10.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Siemens Healthcare
11.1.1 Siemens Healthcare Company Detail
11.1.2 Siemens Healthcare Business Overview
11.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.1.4 Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.1.5 Siemens Healthcare Recent Development
11.2 Celerion
11.2.1 Celerion Company Detail
11.2.2 Celerion Business Overview
11.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.2.4 Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.2.5 Celerion Recent Development
11.3 ZyVersa Therapeutics, Inc.
11.3.1 ZyVersa Therapeutics, Inc. Company Detail
11.3.2 ZyVersa Therapeutics, Inc. Business Overview
11.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.3.4 ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.3.5 ZyVersa Therapeutics, Inc. Recent Development
11.4 Cisbio
11.4.1 Cisbio Company Detail
11.4.2 Cisbio Business Overview
11.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.4.4 Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.4.5 Cisbio Recent Development
11.5 Regeneron Pharmaceuticals, Inc.
11.5.1 Regeneron Pharmaceuticals, Inc. Company Detail
11.5.2 Regeneron Pharmaceuticals, Inc. Business Overview
11.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.5.4 Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.5.5 Regeneron Pharmaceuticals, Inc. Recent Development
11.6 BioPredictive
11.6.1 BioPredictive Company Detail
11.6.2 BioPredictive Business Overview
11.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.6.4 BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.6.5 BioPredictive Recent Development
11.7 Echosens
11.7.1 Echosens Company Detail
11.7.2 Echosens Business Overview
11.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.7.4 Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.7.5 Echosens Recent Development
11.8 Genfit
11.8.1 Genfit Company Detail
11.8.2 Genfit Business Overview
11.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.8.4 Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.8.5 Genfit Recent Development
11.9 Enterome
11.9.1 Enterome Company Detail
11.9.2 Enterome Business Overview
11.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.9.4 Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.9.5 Enterome Recent Development
11.10 NGM Biopharmaceuticals
11.10.1 NGM Biopharmaceuticals Company Detail
11.10.2 NGM Biopharmaceuticals Business Overview
11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Introduction
11.10.4 NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
11.10.5 NGM Biopharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Therapeutics
Table 3. Key Players of Diagnostics
Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2019-2024)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2025-2030)
Table 10. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Trends
Table 11. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Drivers
Table 12. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Challenges
Table 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Restraints
Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players (2019-2024)
Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2023)
Table 17. Ranking of Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Solution and Service
Table 21. Date of Enter into Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2019-2024)
Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Type (2025-2030)
Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2019-2024)
Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Application (2025-2030)
Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2025-2030) & (US$ Million)
Table 46. Siemens Healthcare Company Detail
Table 47. Siemens Healthcare Business Overview
Table 48. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 49. Siemens Healthcare Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 50. Siemens Healthcare Recent Development
Table 51. Celerion Company Detail
Table 52. Celerion Business Overview
Table 53. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 54. Celerion Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 55. Celerion Recent Development
Table 56. ZyVersa Therapeutics, Inc. Company Detail
Table 57. ZyVersa Therapeutics, Inc. Business Overview
Table 58. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 59. ZyVersa Therapeutics, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 60. ZyVersa Therapeutics, Inc. Recent Development
Table 61. Cisbio Company Detail
Table 62. Cisbio Business Overview
Table 63. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 64. Cisbio Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 65. Cisbio Recent Development
Table 66. Regeneron Pharmaceuticals, Inc. Company Detail
Table 67. Regeneron Pharmaceuticals, Inc. Business Overview
Table 68. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 69. Regeneron Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 70. Regeneron Pharmaceuticals, Inc. Recent Development
Table 71. BioPredictive Company Detail
Table 72. BioPredictive Business Overview
Table 73. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 74. BioPredictive Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 75. BioPredictive Recent Development
Table 76. Echosens Company Detail
Table 77. Echosens Business Overview
Table 78. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 79. Echosens Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 80. Echosens Recent Development
Table 81. Genfit Company Detail
Table 82. Genfit Business Overview
Table 83. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 84. Genfit Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 85. Genfit Recent Development
Table 86. Enterome Company Detail
Table 87. Enterome Business Overview
Table 88. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 89. Enterome Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 90. Enterome Recent Development
Table 91. NGM Biopharmaceuticals Company Detail
Table 92. NGM Biopharmaceuticals Business Overview
Table 93. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product
Table 94. NGM Biopharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024) & (US$ Million)
Table 95. NGM Biopharmaceuticals Recent Development
Table 96. Research Programs/Design for This Report
Table 97. Key Data Information from Secondary Sources
Table 98. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Type: 2023 VS 2030
Figure 3. Therapeutics Features
Figure 4. Diagnostics Features
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered
Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region: 2023 VS 2030
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Players in 2023
Figure 14. Global Top Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics as of 2023)
Figure 15. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue in 2023
Figure 16. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2019-2030)
Figure 18. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2019-2030)
Figure 22. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. U.K. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Region (2019-2030)
Figure 30. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. South Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2019-2030)
Figure 38. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Share by Country (2019-2030)
Figure 42. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Siemens Healthcare Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 45. Celerion Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 46. ZyVersa Therapeutics, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 47. Cisbio Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 48. Regeneron Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 49. BioPredictive Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 50. Echosens Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 51. Genfit Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 52. Enterome Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 53. NGM Biopharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Business (2019-2024)
Figure 54. Bottom-up and Top-down Approaches for This Report
Figure 55. Data Triangulation
Figure 56. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
